Logo of Biotron (ASX:BIT)Latest Biotron (ASX:BIT) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

Biotron’s new CEO starts early with SedRx in his sights

Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
9 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Biotron finds strong antiviral activity as SedRx moves toward European trial planning

Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.
Ada Torres
28 Oct 2026

Biotron taps Penthrox veteran to lead its next development phase

Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
14 Oct 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Biotron Reports $1.52M Loss, Advances SedRxTM and HBV Programs Post Sedarex Acquisition

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.
Ada Torres
27 Aug 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

Biotron Navigates EMA Feedback on SedRx and Expands Antiviral Research

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.
Ada Torres
21 July 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Biotron Clears First Regulatory Hurdle for SedRx Anaesthetic

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.
Ada Torres
13 July 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026